Evidence map›Paper›PMID 38256424›Full record

ReviewMedicina (Kaunas, Lithuania)2024

Atypical Complications during the Course of COVID-19: A Comprehensive Review.

Tauqeer Hussain Mallhi, Aqsa Safdar, Muhammad Hammad Butt, Muhammad Salman, Sumbal Nosheen, Zia Ul Mustafa, Faiz Ullah Khan, Yusra Habib Khan

Abstract readReview
In one paragraph

Review in Medicina (Kaunas, Lithuania), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 4 papers.

0numbers the graph read from it
0cells of the map it votes in
4citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

4 citing papers in PubMed.

  1. Article
  2. Clinical Characteristics and Outcome of Readmitted Adult Patients With Acute COVID-19 Infection Within 30 Days of Their Hospital Discharge.The Canadian journal of infectious diseases & medical microbiology = Journal canadien des maladies infectieuses et de la microbiologie medicale · 2025
    Article
  3. Review
  4. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Tauqeer Hussain MallhiDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0001-9957-5362
Aqsa SafdarFaculty of Pharmaceutical Sciences, University of Central Punjab, Lahore 54000, Pakistan.
Muhammad Hammad ButtDepartment of Medicinal Chemistry, Faculty of Pharmacy, Uppsala University, 75123 Uppsala, Sweden.ORCID 0000-0003-4387-1351
Muhammad SalmanInstitute of Pharmacy, Faculty of Pharmaceutical and Allied Health Sciences, Lahore College for Women University, Lahore 54000, Pakistan.ORCID 0000-0002-4366-1461
Sumbal NosheenDepartment of Pharmacy, The Children's Hospital and the University of Child Health Sciences, Lahore 54600, Pakistan.
Zia Ul MustafaDepartment of Pharmacy Services, District Headquarter (DHQ) Hospital, Pakpattan 57400, Pakistan.ORCID 0000-0002-8109-4859
Faiz Ullah KhanDepartment of Pharmacy Administration and Clinical Pharmacy, School of Pharmacy, Xi'an Jiaotong University, Xi'an 710061, China.ORCID 0000-0002-1022-8688
Yusra Habib KhanDepartment of Clinical Pharmacy, College of Pharmacy, Jouf University, Sakaka 72388, Saudi Arabia.ORCID 0000-0002-9479-6147

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

COVID-19 is primarily a respiratory disease, but numerous studies have indicated the involvement of various organ systems during the course of illness. We conducted a comprehensive review of atypical complications of COVID-19 with their incidence range (IR) and their impact on hospitalization and mortality rates. We identified 97 studies, including 55 research articles and 42 case studies. We reviewed four major body organ systems for various types of atypical complications: (i) Gastro-intestinal (GI) and hepatobiliary system, e.g., bowel ischemia/infarction (IR: 1.49-83.87%), GI bleeding/hemorrhage (IR: 0.47-10.6%), hepatic ischemia (IR: 1.0-7.4%); (ii) Neurological system, e.g., acute ischemic stroke/cerebral venous sinus thrombosis/cerebral hemorrhage (IR: 0.5-90.9%), anosmia (IR: 4.9-79.6%), dysgeusia (IR: 2.8-83.38%), encephalopathy/encephalitis with or without fever and hypoxia (IR: 0.19-35.2%); (iii) Renal system, e.g., acute kidney injury (AKI)/acute renal failure (IR: 0.5-68.8%); (iv) Cardiovascular system, e.g., acute cardiac injury/non-coronary myocardial injury (IR: 7.2-55.56%), arrhythmia/ventricular tachycardia/ventricular fibrillation (IR: 5.9-16.7%), and coagulopathy/venous thromboembolism (IR: 19-34.4%). This review encourages and informs healthcare practitioners to keenly monitor COVID-19 survivors for these atypical complications in all major organ systems and not only treat the respiratory symptoms of patients. Post-COVID effects should be monitored, and follow-up of patients should be performed on a regular basis to check for long-term complications.

Indexed as

Acute Kidney InjuryBrain DiseasesCOVID-19Ischemic StrokeHumansIschemiacardiovascular systemcomplicationsCOVID-19gastro-intestinal systemneurological systemrenal system

Identifiers

PMID38256424
PMCPMC10819426

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.